AstraZeneca reveals positive results from Farxiga cardiovascular trial
24th Sep 2018 07:21
(Sharecast News) - AstraZeneca announced positive results from the phase III DECLARE-TIMI 58 cardiovascular outcomes trial for 'Farxiga' dapagliflozin, which it said was the broadest SGLT2 inhibitor cardiovascular outcome trial conducted to date.
Read moreAstraZeneca's Lumoxiti gets FDA approval as hairy cell leukaemia treatment
14th Sep 2018 07:20
(Sharecast News) - AstraZeneca and its global biologics research and development arm MedImmune announced on Friday that the US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukaemia.
Read moreMonday broker round-up
10th Sep 2018 11:48
(Sharecast News) - Glencore: JP Morgan downgrades to neutral with a target price of 370p.
Read moreAstraZeneca gets 'breakthrough' designation for tezepelumab asthma treatment
7th Sep 2018 07:31
(Sharecast News) - AstraZeneca and its partner Amgen announced on Friday that the US Food and Drug Administration (FDA) has granted 'Breakthrough Therapy Designation' for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids or long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.
Read moreAstraZeneca's anifrolumab trial fails to meet primary endpoint
31st Aug 2018 09:00
(Sharecast News) - AstraZeneca and its global biologics research and development arm MedImmune announced top-line results from the TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE) on Friday.
Read moreAstraZeneca gets EC approval for Bydureon BCise
30th Aug 2018 07:23
(Sharecast News) - AstraZeneca announced on Thursday that the European Commission (EC) has approved Bydureon BCise - exenatide 2mg prolonged-release suspension for injection in pre-filled pen - as a new formulation within the marketing authorisation for Bydureon for the treatment of patients with type-2 diabetes.
Read moreAstraZeneca analysing 'inconsistent' results from Bevespi Aerosphere trial
23rd Aug 2018 07:23
(Sharecast News) - AstraZeneca announced top-line results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) on Thursday.
Read moreAstraZeneca gets further approval for Tagrisso in Japan
21st Aug 2018 07:23
(Sharecast News) - AstraZeneca announced on Tuesday that the Japanese Ministry of Health, Labour and Welfare has approved Tagrisso (osimertinib) for the first-line treatment of patients with inoperable or recurrent epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), following priority review.
Read moreAstraZeneca prices four-tranche $3bn global bond offering
15th Aug 2018 08:56
(Sharecast News) - AstraZeneca priced a four-tranche global bond offering totalling $3bn on Tuesday, it announced on Wednesday morning.
Read moreSector movers: Miners, Big Oil and pharma lead gains
7th Aug 2018 18:16
(Sharecast News) - Commodity-related stocks paced gains on Tuesday following the release of figures overnight showing that China's foreign exchange reserves didn't jump last month.
Read moreAstraZeneca, Merck NF1 treatment granted orphan status by EMA
3rd Aug 2018 07:52
(Sharecast News) - AstraZeneca and Merck said the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1) an incurable genetic condition that affects one in 3,000 newborns worldwide.
Read moreAstraZeneca's lung cancer treatment gains positive opinion from CHMP
27th Jul 2018 14:53
(Sharecast News) - AstraZeneca on Friday received a marketing authorisation for its lung cancer treatment Imfinzi from the committee for medicinal products for human use (CHMP).
Read moreAstraZeneca offloads Atacand rights in $200m deal
24th Jul 2018 07:11
(Sharecast News) - AstraZeneca has agreed to sell the commercial rights to Atacand - candesartan cilexetil - and Atacand Plus - a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide - in Europe to Cheplapharm Arzneimittel, it announced on Tuesday.
Read moreFriday broker round-up
17th Feb 2017 09:19
(ShareCast News) - AstraZeneca: Jefferies reiterates Buy with a target price of 5250p. BT Group: Jefferies reiterates Hold with a target price of 325p. Standard Life: Macquarie reiterates Outperform with a target price of 450p. Cobham: Goldman Sachs reiterates Sell with a target price of 88p. Dra
Read moreAstraZeneca reports positive results from breast cancer drug trial
17th Feb 2017 07:08
(ShareCast News) - AstraZeneca on Friday reported positive results from its Phase III OLYMPIAD trial of its breast cancer treatment Lynparza (olaparib). Patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) c
Read more